SlideShare una empresa de Scribd logo
1 de 28
Descargar para leer sin conexión
Virtual screening techniques
Presented by- Presented to-
Rohit Pal Dr. Bhupinder Kumar
M.Pharm (Pharmacuetcal Chemistry, 2nd Semester)
Department of Pharmacuetical Chemistry
ISF College of Pharmacy, Moga (Punjab)
Table of content
• Introduction
• Virtual screening methods
• Ligand based
• Similarity Searching
• Pharmacophore Mapping
• Machinelearning methods
• Structurebased
• Protein LigandDocking
• MeritsandDemerits
• Hybridvirtualscreening
Drug discovery
Introduction
• Virtual screening (VS) is a computational technique
used in drug discovery to search libraries of small
molecules in order to identify those structures which are
most likely to bind to a drug target typically
a protein receptor or enzyme.
• Virtual screening has been defined as the "automatically
evaluating very large libraries of compounds" using
computer programs.
• As this definition suggests, VS has largely been a numbers game
focusing on how the enormous chemical space of over 1060 conceivable
compounds can be filtered to a manageable number that can be
synthesized, purchased, and tested.
• Although searching the entire chemical universe may be a theoretically
interesting problem, more practical VS scenarios focus on designing and
optimizing targeted combinatorial libraries and enriching libraries of
available compounds from in-house compound repositories or vendor
offerings.
• As the accuracy of the method has increased, virtual screening has
become an integral part of the drug discovery process. Virtual Screening
can be used to select in house database compounds for screening, choose
compounds that can be purchased externally, and to choose which
compound should be synthesized next.
r o h I t
F
I
L
T
E
R
Filters—
Shape
Conformers
Any rule like Lipinski’s rule, Veber rule,Ghose rule
Techniques of virtual screening
Virtual screening techniques
Methods of virtual screening
• Ligand-based
• Structure-based
• Hybrid methods
Ligand Based Virtual Screening
• In LBVS process, the most effective biologically active lead
molecule is detected using structural or topological similarity
or pharmacophoric similarity search.
• Taking into consideration several criteria such as structure as
well as shape of individual fragment or electrostatic
properties of the molecule carries out the similarity
comparisons.
• The leads generated are ranked based on their similarity
score, obtained using different methods or algorithms.
Classification of ligand based virtual screening
Similarity Searching
What is it ??
Chemical, pharmacological or biological properties of two compounds match.
The more the common features, the higher the similarity between two molecules.
Chemical
The two structures on top are chemically similar to each other. This is reflected in their common sub-graph, or scaffold: they
share 14 atoms
Pharmacophore
The two structures above are less similar chemically (topologically) yet have the same
pharmacological activity, namely they both are Angiotensin-Converting Enzyme (ACE) inhibitors
Similarity scale
80-99%
100%
60-79%
30-59%
Below 30%
Known inhhbitor
Downloaded library of ligands
2D fingerprints: molecules represented as binary vectors
• Each bit in the bit string (binary vector) represents one molecular fragment. Typical length is ~1000
bits.
• The bit string for a molecule records the presence (“1”) or absence (“0”) of each fragment in the
molecule.
• Originally developed for speeding up substructure search for a query substructure to be present in a
database molecule. Each bit set to “1” in the query must also be set to “1” in the database structure.
• Similarity is based on determining the number of bits that are common to two structures.
3D based similarity
• Shape-based
-ROCS (Rapid Overlay of Chemical
Structures).
- Silicos-it.com (Shape it).
•Computationally more expensive than 2D methods.
•Requires consideration of conformational flexibility
Rigid search - based on a single conformer
−Flexible search.
Pharmacophore Mapping
• Pharmacophore is an abstract description of molecular features which are necessary for molecular
recognition of a ligand by a biological macromolecules.
• Pharmacophore mapping is the definition and placement of pharmacophoric features and the
alignment techniques used to overlay 3-D.
• It consist of three steps:-
1. Identifying common binding element that are responsible for biological activity.
2. Generating potential conformations that active compound may adopt.
3. Determining the 3-D relationship between pharmacophore element in each conformation
generated.
Pharmacophore Mapping Software:
• Window and Linux based protein modelling software.
• Programs that perform pharmacophore based searches are 3D search UNITY, MACCS-3D and
ROCS.
Generating pharmacophore
models: Ligand-based
Rimonabant
Trying to predict how the ligands will bind to the
receptor
without knowing the structure of thereceptor
3-D Pharmacophores
• A three-dimensional pharmacophore specifies the spatial relation-ships between
the groups
• Expressed as distance ranges, angles and planes
Workflow of pharmacophore modeling
Machine learning methods
• SAR Modeling:
 Use knowledge of known active and known inactive compounds to build a
predictive model
 Quantitative-Structure Activity Relationships (QSARs)
 Long established (Hansch analysis, Free-Wilson analysis)
 Generally restricted to small, homogeneous datasets e.g. lead optimization.
 Structure-Activity Relationships (SARs)
 “Activity” data is usually treated qualitatively
 Can be used with data consisting of diverse structural classes and multiple binding modes
 Some resistance to noisy data (HTS data)
 Resulting models used to prioritize compounds for lead finding (not to identify
candidates or drugs)
Structural based virtual screening
• Structural based virtual screening begins with the identification of a potential
ligand-binding site on the target molecule.
• Ideally the target site is a pocket or protuberance having a variety of probable
hydrogen bond donors and acceptors, hydrophobic characteristics, and with
molecular adherence surfaces.
• The ligand-binding site can be the active site as in an enzyme; an assembly site
with another macromolecule or a communication site, which is necessary in the
mechanism of the molecule.
• Determining the structure of a target protein by NMR, X-ray crystallography or
homology modelling befalls as a major and initializing stair in structure based
virtual screening.
• Numerous X-ray crystallographic and NMR studies are helpful in determining the
Virtual Screening perimental structures of ligands bound to the enzymes, serve as a
major source of ideas for analogue design, intern useful for the docking studies.
Methods of structure based virtual screening
Protein LigandDocking
• Computational method which mimics the binding of a ligand to a protein.
• It predicts -
a) The pose(the geometry of the ligand in the binding site of the molecule in the binding site
b) The binding affinity or score representing the strength of binding.
The searchspace
• The difficulty with protein–ligand docking is in part due to the fact that it involves many degrees
of freedom
 The translation and rotation of one molecule relative to another involves six degrees of
freedom
These are in addition the conformational degrees of freedom of both the ligand and the protein
 The solvent may also play a significant role in determining the protein–ligand geometry (often
ignored though)
• The search algorithm generates poses, orientations of particular conformations of the
molecule in the binding site
Tries to cover the search space, if not exhaustively, then as extensively as possible
There is a trade off between time and search space coverage
DockAlgorithms
• DOCK: first docking program by Kuntz et al. 1982
• − Based on shape complementarity and rigid ligands
• Current algorithms
 Fragment-based methods: FlexX, DOCK (since version 4.0)
Monte Carlo/Simulated annealing: QXP(Flo), Autodock,Affinity & LigandFit (Accelrys)
 Genetic algorithms: GOLD, AutoDock (since version 3.0)
 Systematic search: FRED (OpenEye), Glide (Schrödinger)
Merits:
• Computational.
• Only high scoring ligands.
• Reducing real laboratory experiments and accelerates drug discovery.
Demerits:
• Molecular complexity/diversity.
• False positives.
• Synthesis issue.
Hybrid VirtualScreening
Mostly, people in pharmaceutical industry does not follow a specific route they follow a hybrid of methods as discussed in previous
slide.
Shape
Similarity
Structure based
Pharmacophore
Docking based
Screening
Post Process
Starting
database
Potential Lead compounds
Filter : Rule of 5 ,
ADME, TOX
ROCS, FlexS
Pharmacophore
based Screening
Ligand Scout, Phase, Ligand fit
Prepared
database
Dock, Gold, Glide, ICM
Cscore, MM/PBSA, Solvation Corrections
LUDI, Ligand Scout,
Phase, DrugScore
Cleaning Molecules
Remove isotopes, salts and
mixtures
Protonation and
normalization
Remove duplicates and
invalid structures
Filtering Molecules
User defined or other
filter
Remove problematic
moieties using PAINS,
Frequent Hitters etc.
PhyChem property
descriptor calculation
and filtration
Apply protonation at
pH 7.4
THANK UOU

Más contenido relacionado

La actualidad más candente

De novo drug design
De novo drug designDe novo drug design
De novo drug designmojdeh y
 
CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)Pinky Vincent
 
Pharmacophore mapping
Pharmacophore mapping Pharmacophore mapping
Pharmacophore mapping GamitKinjal
 
3 d qsar approaches structure
3 d qsar approaches structure3 d qsar approaches structure
3 d qsar approaches structureROHIT PAL
 
Molecular docking
Molecular dockingMolecular docking
Molecular dockingRahul B S
 
Traditional and Rational Drug Designing
Traditional and Rational Drug DesigningTraditional and Rational Drug Designing
Traditional and Rational Drug DesigningManish Kumar
 
Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)Theabhi.in
 
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)Satigayatri
 
Combinatorial chemistry and high throughput screening
Combinatorial chemistry and high throughput screeningCombinatorial chemistry and high throughput screening
Combinatorial chemistry and high throughput screeningAnji Reddy
 
Energy minimization methods - Molecular Modeling
Energy minimization methods - Molecular ModelingEnergy minimization methods - Molecular Modeling
Energy minimization methods - Molecular ModelingChandni Pathak
 
Rational drug design method
Rational drug design methodRational drug design method
Rational drug design methodRangnathChikane
 
Structure based in silico virtual screening
Structure based in silico virtual screeningStructure based in silico virtual screening
Structure based in silico virtual screeningJoon Jyoti Sahariah
 

La actualidad más candente (20)

De novo drug design
De novo drug designDe novo drug design
De novo drug design
 
CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)
 
Denovo Drug Design
Denovo Drug DesignDenovo Drug Design
Denovo Drug Design
 
Pharmacophore mapping
Pharmacophore mapping Pharmacophore mapping
Pharmacophore mapping
 
3 d qsar approaches structure
3 d qsar approaches structure3 d qsar approaches structure
3 d qsar approaches structure
 
Molecular docking
Molecular dockingMolecular docking
Molecular docking
 
MOLECULAR DOCKING
MOLECULAR DOCKINGMOLECULAR DOCKING
MOLECULAR DOCKING
 
Traditional and Rational Drug Designing
Traditional and Rational Drug DesigningTraditional and Rational Drug Designing
Traditional and Rational Drug Designing
 
Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)
 
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
 
Docking
DockingDocking
Docking
 
docking
docking docking
docking
 
Rational drug design
Rational drug designRational drug design
Rational drug design
 
De Novo Drug Design
De Novo Drug DesignDe Novo Drug Design
De Novo Drug Design
 
Combinatorial chemistry and high throughput screening
Combinatorial chemistry and high throughput screeningCombinatorial chemistry and high throughput screening
Combinatorial chemistry and high throughput screening
 
Energy minimization methods - Molecular Modeling
Energy minimization methods - Molecular ModelingEnergy minimization methods - Molecular Modeling
Energy minimization methods - Molecular Modeling
 
3D QSAR
3D QSAR3D QSAR
3D QSAR
 
Rational drug design method
Rational drug design methodRational drug design method
Rational drug design method
 
Target Validation
Target ValidationTarget Validation
Target Validation
 
Structure based in silico virtual screening
Structure based in silico virtual screeningStructure based in silico virtual screening
Structure based in silico virtual screening
 

Similar a Virtual screening techniques

Docking based screening of drugs.
Docking based screening of drugs.Docking based screening of drugs.
Docking based screening of drugs.Himanshu Yadav
 
molecular docking screnning. pptx
molecular docking screnning. pptxmolecular docking screnning. pptx
molecular docking screnning. pptxPraveen kumar S
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSDENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSShikha Popali
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARM
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARMDENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARM
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARMShikha Popali
 
Target oriented generic fingerprint-based molecular representation
Target oriented generic fingerprint-based molecular representationTarget oriented generic fingerprint-based molecular representation
Target oriented generic fingerprint-based molecular representationcsandit
 
Virtual screening ppt
Virtual screening pptVirtual screening ppt
Virtual screening pptVivekYadav490
 
Cadd - Computer Aided Drug Design
Cadd - Computer Aided Drug DesignCadd - Computer Aided Drug Design
Cadd - Computer Aided Drug DesignZaid Wani
 
Computer Aided Molecular Modeling
Computer Aided Molecular ModelingComputer Aided Molecular Modeling
Computer Aided Molecular Modelingpkchoudhury
 
Structure based drug design- kiranmayi
Structure based drug design- kiranmayiStructure based drug design- kiranmayi
Structure based drug design- kiranmayiKiranmayiKnv
 
Cadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmCadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmShikha Popali
 
1 -val_gillet_-_ligand-based_and_structure-based_virtual_screening
1  -val_gillet_-_ligand-based_and_structure-based_virtual_screening1  -val_gillet_-_ligand-based_and_structure-based_virtual_screening
1 -val_gillet_-_ligand-based_and_structure-based_virtual_screeningDeependra Ban
 
cadd-191129134050 (1).pptx
cadd-191129134050 (1).pptxcadd-191129134050 (1).pptx
cadd-191129134050 (1).pptxNoorelhuda2
 
Methods in Rational Drug design.pptx
Methods in Rational Drug design.pptxMethods in Rational Drug design.pptx
Methods in Rational Drug design.pptxashharnomani
 
pharmacophoremapping05-180503150916-converted.pptx
pharmacophoremapping05-180503150916-converted.pptxpharmacophoremapping05-180503150916-converted.pptx
pharmacophoremapping05-180503150916-converted.pptxashharnomani
 
Fragment based drug design
Fragment based drug designFragment based drug design
Fragment based drug designEkta Tembhare
 

Similar a Virtual screening techniques (20)

Docking based screening of drugs.
Docking based screening of drugs.Docking based screening of drugs.
Docking based screening of drugs.
 
molecular docking screnning. pptx
molecular docking screnning. pptxmolecular docking screnning. pptx
molecular docking screnning. pptx
 
Computer aided drug design
Computer aided drug designComputer aided drug design
Computer aided drug design
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSDENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARM
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARMDENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARM
DENOVO DRUG DESIGN AS PER PCI SYLLABUS M.PHARM
 
Target oriented generic fingerprint-based molecular representation
Target oriented generic fingerprint-based molecular representationTarget oriented generic fingerprint-based molecular representation
Target oriented generic fingerprint-based molecular representation
 
Virtual screening ppt
Virtual screening pptVirtual screening ppt
Virtual screening ppt
 
Cadd assignment 4 (sarita)
Cadd assignment 4 (sarita)Cadd assignment 4 (sarita)
Cadd assignment 4 (sarita)
 
Cadd - Computer Aided Drug Design
Cadd - Computer Aided Drug DesignCadd - Computer Aided Drug Design
Cadd - Computer Aided Drug Design
 
Computer Aided Molecular Modeling
Computer Aided Molecular ModelingComputer Aided Molecular Modeling
Computer Aided Molecular Modeling
 
Structure based drug design- kiranmayi
Structure based drug design- kiranmayiStructure based drug design- kiranmayi
Structure based drug design- kiranmayi
 
Cadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmCadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.Pharm
 
1 -val_gillet_-_ligand-based_and_structure-based_virtual_screening
1  -val_gillet_-_ligand-based_and_structure-based_virtual_screening1  -val_gillet_-_ligand-based_and_structure-based_virtual_screening
1 -val_gillet_-_ligand-based_and_structure-based_virtual_screening
 
CADD assignment unit 3
CADD assignment unit 3CADD assignment unit 3
CADD assignment unit 3
 
cadd-191129134050 (1).pptx
cadd-191129134050 (1).pptxcadd-191129134050 (1).pptx
cadd-191129134050 (1).pptx
 
Methods in Rational Drug design.pptx
Methods in Rational Drug design.pptxMethods in Rational Drug design.pptx
Methods in Rational Drug design.pptx
 
pharmacophoremapping05-180503150916-converted.pptx
pharmacophoremapping05-180503150916-converted.pptxpharmacophoremapping05-180503150916-converted.pptx
pharmacophoremapping05-180503150916-converted.pptx
 
Fragment based drug design
Fragment based drug designFragment based drug design
Fragment based drug design
 
CADD
CADDCADD
CADD
 
Applied Bioinformatics Assignment 5docx
Applied Bioinformatics Assignment  5docxApplied Bioinformatics Assignment  5docx
Applied Bioinformatics Assignment 5docx
 

Más de ROHIT PAL

Antitubercular drugs
Antitubercular drugsAntitubercular drugs
Antitubercular drugsROHIT PAL
 
Phase transfer catalysis
Phase transfer catalysisPhase transfer catalysis
Phase transfer catalysisROHIT PAL
 
Fermentation
FermentationFermentation
FermentationROHIT PAL
 
X ray crystallography
X ray crystallographyX ray crystallography
X ray crystallographyROHIT PAL
 
Enantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokineticsEnantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokineticsROHIT PAL
 
Introduction to alkaloids
Introduction to alkaloidsIntroduction to alkaloids
Introduction to alkaloidsROHIT PAL
 
Anticancer drugs persentation
Anticancer drugs persentationAnticancer drugs persentation
Anticancer drugs persentationROHIT PAL
 

Más de ROHIT PAL (7)

Antitubercular drugs
Antitubercular drugsAntitubercular drugs
Antitubercular drugs
 
Phase transfer catalysis
Phase transfer catalysisPhase transfer catalysis
Phase transfer catalysis
 
Fermentation
FermentationFermentation
Fermentation
 
X ray crystallography
X ray crystallographyX ray crystallography
X ray crystallography
 
Enantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokineticsEnantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokinetics
 
Introduction to alkaloids
Introduction to alkaloidsIntroduction to alkaloids
Introduction to alkaloids
 
Anticancer drugs persentation
Anticancer drugs persentationAnticancer drugs persentation
Anticancer drugs persentation
 

Último

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentationmarwaahmad357
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 

Último (20)

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentation
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 

Virtual screening techniques

  • 1. Virtual screening techniques Presented by- Presented to- Rohit Pal Dr. Bhupinder Kumar M.Pharm (Pharmacuetcal Chemistry, 2nd Semester) Department of Pharmacuetical Chemistry ISF College of Pharmacy, Moga (Punjab)
  • 2. Table of content • Introduction • Virtual screening methods • Ligand based • Similarity Searching • Pharmacophore Mapping • Machinelearning methods • Structurebased • Protein LigandDocking • MeritsandDemerits • Hybridvirtualscreening
  • 4. Introduction • Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target typically a protein receptor or enzyme. • Virtual screening has been defined as the "automatically evaluating very large libraries of compounds" using computer programs.
  • 5. • As this definition suggests, VS has largely been a numbers game focusing on how the enormous chemical space of over 1060 conceivable compounds can be filtered to a manageable number that can be synthesized, purchased, and tested. • Although searching the entire chemical universe may be a theoretically interesting problem, more practical VS scenarios focus on designing and optimizing targeted combinatorial libraries and enriching libraries of available compounds from in-house compound repositories or vendor offerings. • As the accuracy of the method has increased, virtual screening has become an integral part of the drug discovery process. Virtual Screening can be used to select in house database compounds for screening, choose compounds that can be purchased externally, and to choose which compound should be synthesized next.
  • 6. r o h I t F I L T E R Filters— Shape Conformers Any rule like Lipinski’s rule, Veber rule,Ghose rule
  • 9. Methods of virtual screening • Ligand-based • Structure-based • Hybrid methods
  • 10. Ligand Based Virtual Screening • In LBVS process, the most effective biologically active lead molecule is detected using structural or topological similarity or pharmacophoric similarity search. • Taking into consideration several criteria such as structure as well as shape of individual fragment or electrostatic properties of the molecule carries out the similarity comparisons. • The leads generated are ranked based on their similarity score, obtained using different methods or algorithms.
  • 11. Classification of ligand based virtual screening
  • 12. Similarity Searching What is it ?? Chemical, pharmacological or biological properties of two compounds match. The more the common features, the higher the similarity between two molecules. Chemical The two structures on top are chemically similar to each other. This is reflected in their common sub-graph, or scaffold: they share 14 atoms Pharmacophore The two structures above are less similar chemically (topologically) yet have the same pharmacological activity, namely they both are Angiotensin-Converting Enzyme (ACE) inhibitors
  • 13. Similarity scale 80-99% 100% 60-79% 30-59% Below 30% Known inhhbitor Downloaded library of ligands
  • 14. 2D fingerprints: molecules represented as binary vectors • Each bit in the bit string (binary vector) represents one molecular fragment. Typical length is ~1000 bits. • The bit string for a molecule records the presence (“1”) or absence (“0”) of each fragment in the molecule. • Originally developed for speeding up substructure search for a query substructure to be present in a database molecule. Each bit set to “1” in the query must also be set to “1” in the database structure. • Similarity is based on determining the number of bits that are common to two structures.
  • 15. 3D based similarity • Shape-based -ROCS (Rapid Overlay of Chemical Structures). - Silicos-it.com (Shape it). •Computationally more expensive than 2D methods. •Requires consideration of conformational flexibility Rigid search - based on a single conformer −Flexible search.
  • 16. Pharmacophore Mapping • Pharmacophore is an abstract description of molecular features which are necessary for molecular recognition of a ligand by a biological macromolecules. • Pharmacophore mapping is the definition and placement of pharmacophoric features and the alignment techniques used to overlay 3-D. • It consist of three steps:- 1. Identifying common binding element that are responsible for biological activity. 2. Generating potential conformations that active compound may adopt. 3. Determining the 3-D relationship between pharmacophore element in each conformation generated. Pharmacophore Mapping Software: • Window and Linux based protein modelling software. • Programs that perform pharmacophore based searches are 3D search UNITY, MACCS-3D and ROCS.
  • 17. Generating pharmacophore models: Ligand-based Rimonabant Trying to predict how the ligands will bind to the receptor without knowing the structure of thereceptor
  • 18. 3-D Pharmacophores • A three-dimensional pharmacophore specifies the spatial relation-ships between the groups • Expressed as distance ranges, angles and planes
  • 20. Machine learning methods • SAR Modeling:  Use knowledge of known active and known inactive compounds to build a predictive model  Quantitative-Structure Activity Relationships (QSARs)  Long established (Hansch analysis, Free-Wilson analysis)  Generally restricted to small, homogeneous datasets e.g. lead optimization.  Structure-Activity Relationships (SARs)  “Activity” data is usually treated qualitatively  Can be used with data consisting of diverse structural classes and multiple binding modes  Some resistance to noisy data (HTS data)  Resulting models used to prioritize compounds for lead finding (not to identify candidates or drugs)
  • 21. Structural based virtual screening • Structural based virtual screening begins with the identification of a potential ligand-binding site on the target molecule. • Ideally the target site is a pocket or protuberance having a variety of probable hydrogen bond donors and acceptors, hydrophobic characteristics, and with molecular adherence surfaces. • The ligand-binding site can be the active site as in an enzyme; an assembly site with another macromolecule or a communication site, which is necessary in the mechanism of the molecule. • Determining the structure of a target protein by NMR, X-ray crystallography or homology modelling befalls as a major and initializing stair in structure based virtual screening. • Numerous X-ray crystallographic and NMR studies are helpful in determining the Virtual Screening perimental structures of ligands bound to the enzymes, serve as a major source of ideas for analogue design, intern useful for the docking studies.
  • 22. Methods of structure based virtual screening
  • 23. Protein LigandDocking • Computational method which mimics the binding of a ligand to a protein. • It predicts - a) The pose(the geometry of the ligand in the binding site of the molecule in the binding site b) The binding affinity or score representing the strength of binding.
  • 24. The searchspace • The difficulty with protein–ligand docking is in part due to the fact that it involves many degrees of freedom  The translation and rotation of one molecule relative to another involves six degrees of freedom These are in addition the conformational degrees of freedom of both the ligand and the protein  The solvent may also play a significant role in determining the protein–ligand geometry (often ignored though) • The search algorithm generates poses, orientations of particular conformations of the molecule in the binding site Tries to cover the search space, if not exhaustively, then as extensively as possible There is a trade off between time and search space coverage
  • 25. DockAlgorithms • DOCK: first docking program by Kuntz et al. 1982 • − Based on shape complementarity and rigid ligands • Current algorithms  Fragment-based methods: FlexX, DOCK (since version 4.0) Monte Carlo/Simulated annealing: QXP(Flo), Autodock,Affinity & LigandFit (Accelrys)  Genetic algorithms: GOLD, AutoDock (since version 3.0)  Systematic search: FRED (OpenEye), Glide (Schrödinger)
  • 26. Merits: • Computational. • Only high scoring ligands. • Reducing real laboratory experiments and accelerates drug discovery. Demerits: • Molecular complexity/diversity. • False positives. • Synthesis issue.
  • 27. Hybrid VirtualScreening Mostly, people in pharmaceutical industry does not follow a specific route they follow a hybrid of methods as discussed in previous slide. Shape Similarity Structure based Pharmacophore Docking based Screening Post Process Starting database Potential Lead compounds Filter : Rule of 5 , ADME, TOX ROCS, FlexS Pharmacophore based Screening Ligand Scout, Phase, Ligand fit Prepared database Dock, Gold, Glide, ICM Cscore, MM/PBSA, Solvation Corrections LUDI, Ligand Scout, Phase, DrugScore Cleaning Molecules Remove isotopes, salts and mixtures Protonation and normalization Remove duplicates and invalid structures Filtering Molecules User defined or other filter Remove problematic moieties using PAINS, Frequent Hitters etc. PhyChem property descriptor calculation and filtration Apply protonation at pH 7.4